1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress
Year: 2021
Type: article
Source: Annals of Oncology
Institutions: University of Chicago, Duke Medical Center, National Cancer Center Hospital East, Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, City of Hope, Mayo Clinic, Mayo Clinic in Arizona, University of Southern California, USC Norris Comprehensive Cancer Center, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Seagen (United States), Georgetown University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Pancreatic Cancer Action Network, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Celgene, Array BioPharma, Taiho Pharmaceutical, Exelixis, Les Laboratories Pierre Fabre, Clovis Oncology, Five Prime Therapeutics, Jounce Therapeutics, Myriad Genetics, Mirati Therapeutics, BeiGene, Incyte, Celltrion, Seagen, Natera, Eisai, Astellas Pharma, Servier, Swedish Orphan Biovitrum, Ono Pharmaceutical, Ipsen, Mereo BioPharma, Genentech, Samsung, Chugai Pharmaceutical, Bayer Yakuhin, Foundation Medicine, Instituto de Salud Carlos III, Daiichi Sankyo Europe
OpenAlex ID: W3188643573